ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 54 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,532,830 | +0.3% | 2,404,614 | -10.0% | 18.21% | +1.2% |
| Q2 2023 | $27,452,452 | +13.4% | 2,670,472 | -14.8% | 17.99% | -10.9% |
| Q1 2023 | $24,211,256 | +5.4% | 3,136,173 | +0.3% | 20.18% | +1.6% |
| Q4 2022 | $22,977,372 | +4.4% | 3,126,173 | +2.3% | 19.87% | +0.1% |
| Q3 2022 | $22,006,000 | +34.2% | 3,056,420 | +58.6% | 19.85% | +42.1% |
| Q2 2022 | $16,398,000 | +23.1% | 1,926,869 | +29.8% | 13.97% | +13.0% |
| Q1 2022 | $13,318,000 | -23.8% | 1,484,693 | +17.7% | 12.36% | -18.9% |
| Q4 2021 | $17,478,000 | – | 1,261,927 | – | 15.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |